IgA肾病的诊治进展  

Advances in Diagnosis and Treatment of IgA Nephropathy

作　　者：高源 魏明明[2] 李新建[2] 徐璐[2] 董辉辉 

机构地区：[1]济宁医学院临床医学院,山东 济宁 [2]济宁医学院附属医院,山东 济宁

出　　处：《临床医学进展》2022年第9期8139-8144,共6页Advances in Clinical Medicine

摘　　要：截至目前研究表明,免疫球蛋白A肾病(IgA nephropathy, IgAN)仍然是最常见的原发性肾小球肾炎,是慢性肾脏疾病的主要原因,或进展为终末期肾脏病。如今,肾活检仍被认定为诊断IgAN的“金标准”,表现为IgA肾小球沉积为主,通常伴有局部细胞增殖和基质扩张。目前IgAN发病机制尚不清晰,临床上应用的治疗方案尚未统一。本文主要就当前IgAN诊治与预后进行综述。Immunoglobulin A nephropathy (IgAN) remains the most common primary glomerulonephritis and the leading cause of chronic kidney disease or progression to end-stage renal disease. Today, renal biopsy is still recognized as the “gold standard” for the diagnosis of IgAN, showing predominantly IgA glomerular deposition, often accompanied by local cell proliferation and stromal expansion. At present, the pathogenesis of IgAN is still unclear, and the clinical treatment has not been unified. This article mainly reviews the current diagnosis, treatment and prognosis of IgAN.

关 键 词：原发性IGA肾病 肾小球肾炎 预后 

分 类 号：R692.31[医药卫生—泌尿科学]